IP Library Granted Patent US 6,872,397
Granted Patent B2
US 6,872,397 · App. 09/812,113 · Granted Mar 29, 2005

Method for treating neuromuscular disorders and conditions with botulinum toxin types A and B

Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,872,397
App. No.
09/812,113
Granted
Mar 29, 2005
Kind
B2
Abstract

A method of treating a patient suffering from a disease, disorder or condition includes the administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient a therapeutically effective amount of another botulinum toxin of a different serotype.

Claims (5)

1. A method of treating a patient suffering from a dystonial the method comprising intramuscular or subcutaneous administration to the patient of up to 1,000 units of a botulinum toxin type A per patient treatment session until the patient experiences loss of clinical response to the administered botulinum toxin type A, as determined by a failure of the administered botulinum toxin type A to achieve a marked reduction of or to substantially alleviate a symptom of the dystonia, and thereafter administering to the patient at least about 80 units of a botulinum toxin type B to thereby again achieve a marked reduction or a substantial alleviation of a symptom of the dystonia.

2. The method of claim 1 , wherein the dystonia is cervical dystonia.

3. A method of treating cervical dystonia in a patient, the method comprising intramuscular or subcutaneous administration to a patient with dystonia of up to 1,000 units of a botulinum toxin type A per patient treatment session until th patient experiences loss of clinical response to the administered botulinum toxin type A, as determined by a failure of the administered botulinum toxin type A to achieve a marked reduction of a symptom of the cervical dystonia, and thereafter administering to the patient at least about 80 units of a botulinum toxin type B.

4. The method of claim 3 , wherein treating the cervical dystonia reduces the severity of an abnormal head position symptom of the cervical dystonia.

5. The method of claim 3 , wherein treating the cervical dystonia reduces a neck pain associated with the cervical dystonia.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2014
From: JPMORGAN CHASE BANK, N.A.
To: SOLSTICE NEUROSCIENCES, LLC
Reel/Frame 033987/0440 →
SECURITY AGREEMENT Recorded Sep 26, 2012
From: SOLSTICE NEUROSCIENCES, LLC
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 029041/0720 →
MERGER Recorded Sep 6, 2012
From: SOLSTICE NEUROSCIENCES, INC.
To: SOLSTICE NEUROSCIENCES, LLC
Reel/Frame 028917/0475 →
RELEASE AND REASSIGNMENT Recorded Aug 10, 2010
From: NEXBANK, SSB
To: SOLSTICE NEUROSCIENCES, INC.
Reel/Frame 024812/0653 →
SECURITY AGREEMENT Recorded Mar 6, 2007
From: SOLSTICE NEUROSCIENCES, INC.
To: NEXBANK, SSB
Reel/Frame 018969/0513 →
Continuity (2)
Continuation 0807504800 · Jun 10, 1993
Related Publication 20010012833A1 · Aug 9, 2001